In this retrospective cohort of patients with advanced BRAF-mutant melanoma treated with BRAFi/MEKi, systemic antibiotic exposure within 30, 60, or 90 days before and after therapy initiation was not significantly associated with inferior PFS, OS, or ORR. Here, BRAF is linked to melanoma.